Perflutren (OPTISON perflutren 570 microgram/3mL injection vial)
Perflutren risk profile, scheduling, and guidance for claims professionals and care workers . Also known as OPTISON perflutren 570 microgram/3mL injection vial, DEFINITY perflutren lipid microsphere injection vial.
Perflutren (brand names: OPTISON perflutren 570 microgram/3mL injection vial, DEFINITY perflutren lipid microsphere injection vial) is classified as Minimal risk by AllMeds. It is a S4 medication under the TGA in Australia. Ultrasound contrast agent with no ongoing effects on workplace safety.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Minimal (0 points)
- Recommended maximum duration: 1 days
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | Not PBS listed |
Risk Profile
Ultrasound contrast agent with no ongoing effects on workplace safety.
Regulatory and Compliance Guidance
When Perflutren appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Need to assess this medication across your caseload?
Run a full risk assessment including Perflutren interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.